Listed

Stryker Corp: Form 10-Q for the period ended Sep 30, 2026

Filed with the SEC on Oct 30, 2026 and accepted by EDGAR at Oct 30, 2026, 11:08 ET.

Share

Management's discussion and analysis

As filed, 50,090 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

ABOUT STRYKER

Stryker Corporation ("we" or the "Company") is a global leader in

medical technologies and, together with our customers, we are

driven to make healthcare better. We offer innovative products

and services in MedSurg, Neurotechnology, and Orthopaedics

that help improve patient and healthcare outcomes. Alongside

our customers around the world, we impact more than 150 million

patients annually. Our goal is to achieve sales growth at the high-

end of the medical technology (MedTech) industry and maintain

our long-term capital allocation strategy that prioritizes: (1)

Acquisitions, (2) Dividends and (3) Share repurchases.

MedSurg and Neurotechnology products include surgical

equipment, patient and caregiver safety technologies, and a

comprehensive line of products for traditional brain and open

skull-based surgical procedures orthobiologic and biosurgery

products, including synthetic bone grafts and vertebral

augmentation (Instruments), endoscopic and communications

systems (Endoscopy), patient handling, emergency medical

equipment, intensive care disposable products, clinical

communication and artificial intelligence-assisted virtual care

platform technology (Medical), and minimally invasive products

for the treatment of acute ischemic and hemorrhagic stroke and

venous thromboembolism (Vascular). Orthopaedics products

include implants and surgical equipment such as navigation

systems and robotics used in total joint replacements, such as

hip, knee and shoulder, ankle and trauma and extremities

surgeries. We bring patients and physicians advanced implant

designs and specialized instrumentation that make orthopaedic

surgery and recovery simpler, faster and more effective. We

support surgeons with technologies, products and services they

need to support each patient’s clinical challenge.

Overview of the Three and Nine Months

In the three months 2026 we achieved sales growth of 7.7% from

2025. Organic net sales increased 7.7%, primarily driven by

increased unit volume. We reported operating income margin of

15.9%, net earnings of $753 and net earnings per diluted share

of $1.96. Excluding the impact of certain items, adjusted

operating income margin(1) increased by 60 basis points to

26.2%, with adjusted net earnings(1) of $1,357 and adjusted net

earnings per diluted share(1) of $3.52, an increase of 10.3% from

In the nine months 2026 we achieved sales growth of 6.6% from

2025. Excluding the impact of acquisitions and divestitures,

organic net sales increased 6.4%, primarily driven by increased

unit volume. We reported operating income margin of 19.0%, net

earnings of $2,774 and net earnings per diluted share of $7.19.

Excluding the impact of certain items, adjusted operating income

margin(1) increased by 30 basis points to 25.0%, with adjusted

net earnings(1) of $3,785 and adjusted net earnings per diluted

share(1) of $9.81, an increase of 7.1% from 2025.

(1) Refer to "Non-GAAP Financial Measures" for a discussion of non-

GAAP financial measures used in this report and a reconciliation to the

most directly comparable GAAP financial measure.

CONSOLIDATED RESULTS OF OPERATIONS Three Months 2026 2025 Percent Net Sales 2026 2025 Percentage Change Nine Months 2026 2025 Percent Net Sales 2026 2025 Percentage Change
Net sales $6,520 $6,057 100.0% 100.0% 7.7% $19,129 $17,945 100.0% 100.0% 6.6%
Gross profit 4,248 3,852 65.2 63.6 10.3 12,556 11,437 65.6 63.7 9.8
Research, development and engineering expenses 433 410 6.6 6.8 5.6 1,280 1,222 6.7 6.8 4.7
Selling, general and administrative expenses 2,313 2,045 35.5 33.8 13.1 6,823 6,424 35.7 35.8 6.2
Amortization of intangible assets 175 189 2.7 3.1 (7.4) 530 543 2.8 3.0 (2.4)
Goodwill and other impairments 293 73 4.5 1.2 nm 294 163 1.5 0.9 nm
Interest expense (143) (157) (2.2) (2.6) (8.9) (432) (453) (2.3) (2.5) (4.6)
Other income 106 51 1.6 0.8 107.8 214 177 1.1 1.0 20.9
Income taxes 244 170 nm nm 43.5 637 412 nm nm 54.6
Net earnings $753 $859 11.5% 14.2% (12.3)% $2,774 $2,397 14.5% 13.4% 15.7%
Net earnings per diluted share $1.96 $2.22 (11.7)% $7.19 $6.20 16.0%
Adjusted net earnings per diluted share(1) $3.52 $3.19 10.3% $9.81 $9.16 7.1%

nm - not meaningful

Dollar amounts are in millions except per share amounts or as otherwise specified. 12

STRYKER CORPORATION 2026 Third Quarter Form 10-Q

SALES GROWTH ANALYSIS

MedSurg and Neurotechnology: Instruments Three Months 2026 2025 Percentage Change As Reported Constant Currency Nine Months 2026 2025 Percentage Change As Reported Constant Currency
United States $835 $797 4.8% 4.8% $2,441 $2,275 7.4% 7.4%
International 161 152 6.5 7.1 478 430 11.3 8.8
Total $996 $949 5.1% 5.2% $2,919 $2,705 8.0% 7.6%
Endoscopy
United States $839 $743 13.0% 13.0% $2,359 $2,195 7.5% 7.5%
International 182 153 18.0 18.5 534 467 14.2 11.4
Total $1,021 $896 13.9% 14.0% $2,893 $2,662 8.7% 8.2%
Medical
United States $910 $827 10.0% 10.0% $2,602 $2,469 5.4% 5.4%
International 171 158 8.1 8.5 503 451 11.4 8.2
Total $1,081 $985 9.7% 9.8% $3,105 $2,920 6.3% 5.8%
Vascular
United States $320 $283 13.0% 13.0% $850 $754 12.7% 12.7%
International 246 242 2.1 0.8 729 675 8.0 4.9
Total $566 $525 8.0% 7.4% $1,579 $1,429 10.5% 9.0%
MedSurg and Neurotechnology
United States $2,904 $2,650 9.6% 9.6% $8,252 $7,693 7.3% 7.3%
International 760 705 7.8 7.7 2,244 2,023 10.9 8.0
Total $3,664 $3,355 9.2% 9.2% $10,496 $9,716 8.0% 7.4%
Orthopaedics:
Knees
United States $458 $452 1.3% 1.3% $1,418 $1,376 3.0% 3.0%
International 177 176 0.5 1.1 580 531 9.3 6.6
Total $635 $628 1.1% 1.2% $1,998 $1,907 4.8% 4.0%
Hips
United States $277 $279 (0.6)% (0.6)% $849 $831 2.2% 2.2%
International 176 178 (1.7) (0.8) 543 535 1.4 (0.6)
Total $453 $457 (1.0)% (0.7)% $1,392 $1,366 1.9% 1.1%
Trauma and Extremities
United States $735 $703 4.5% 4.5% $2,293 $2,118 8.2% 8.2%
International 275 257 7.5 8.4 824 744 10.9 7.9
Total $1,010 $960 5.3% 5.5% $3,117 $2,862 8.9% 8.1%
Ortho Tech
United States $576 $487 18.1% 18.1% $1,573 $1,429 10.0% 10.0%
International 178 164 9.0 9.5 544 488 11.6 9.3
Total $754 $651 15.8% 16.0% $2,117 $1,917 10.4% 9.8%
$2,852 $2,696 5.8% 6.0% $8,624 $8,052 7.1% 6.4%
Spinal Implants
United States $— $— —% —% $— $118 (100.0)% (100.0)%
International 4 6 (43.9) (45.4) 9 59 (85.7) (87.1)
Total $4 $6 (43.9)% (45.4)% $9 $177 (95.2)% (95.5)%
Orthopaedics
United States $2,046 $1,921 6.5% 6.5% $6,133 $5,872 4.4% 4.4%
International 810 781 3.8 4.5 2,500 2,357 6.1 3.5
Total $2,856 $2,702 5.7% 5.9% $8,633 $8,229 4.9% 4.1%
Geographic:
United States $4,950 $4,571 8.3% 8.3% $14,385 $13,565 6.0% 6.0%
International 1,570 1,486 5.7 6.0 4,744 4,380 8.3 5.6
Total $6,520 $6,057 7.7% 7.7% $19,129 $17,945 6.6% 5.9%

Note: In the first quarter 2026 we announced a change in our organizational structure. Our new Ortho Tech business combines the

orthopaedic instruments portfolio (Orthopaedic Instruments) from Instruments with Other Orthopaedics. In addition, Neuro Cranial and

the spine enabling technologies portfolio (Enabling Technologies) from Other Orthopaedics were combined with the remaining

Instruments business to align with our internal reporting structure. Ortho Tech includes sales related to Orthopaedic Instruments of $535

and $492 and Other Orthopaedics of $219 and $159 for the three months 2026 and 2025. For the nine months 2026 and 2025 Ortho

Tech includes sales related to Orthopaedic Instruments of $1,547 and $1,477 and Other Orthopaedics of $570 and $440. Instruments

includes sales related to Neuro Cranial of $670 and $637 and Enabling Technologies of $28 and $45 for the three months 2026 and

2025. For the nine months 2026 and 2025 Instruments includes sales related to Neuro Cranial of $1,957 and $1,816 and Enabling

Technologies of $82 and $108. We have reflected these changes in all historical periods presented.

Dollar amounts are in millions except per share amounts or as otherwise specified. 13

STRYKER CORPORATION 2026 Third Quarter Form 10-Q

Consolidated Net Sales

Consolidated net sales increased 7.7% in the three months 2026

on both a reported and constant currency basis. Net sales in

constant currency increased by 7.6% from increased unit volume

and 0.1% due to higher prices. The unit volume increase was due

to higher product shipments across all MedSurg and

Neurotechnology businesses and certain Orthopaedics

businesses.

Consolidated net sales increased 6.6% in the nine months 2026

as reported and 5.9% in constant currency as foreign currency

exchange rates positively impacted net sales by 0.7%. Excluding

the (0.5)% impact of acquisitions and divestitures, net sales in

constant currency increased by 6.2% from increased unit volume

and 0.2% due to higher prices. The unit volume increase was due

to higher product shipments across all MedSurg and

Neurotechnology businesses and most Orthopaedics businesses.

MedSurg and Neurotechnology Net Sales

MedSurg and Neurotechnology net sales increased 9.2% in the

three months 2026 on both a reported and constant currency

basis. Excluding the 0.1% impact of acquisitions and divestitures,

net sales in constant currency increased by 8.9% from increased

unit volume and 0.2% from higher prices. The unit volume

increase was due to higher shipments across all Medsurg and

Neurotechnology businesses.

MedSurg and Neurotechnology net sales increased 8.0% in the

nine months 2026 as reported and 7.4% in constant currency, as

foreign currency exchange rates positively impacted net sales by

0.6%. Excluding the 0.8% impact of acquisitions and divestitures,

net sales in constant currency increased by 6.3% from increased

unit volume and 0.3% from higher prices. The unit volume

increase was due to higher shipments across all MedSurg and

Neurotechnology businesses.

Orthopaedics Net Sales

Orthopaedics net sales increased 5.7% in the three months 2026

as reported and 5.9% in constant currency, as foreign currency

exchange rates negatively impacted net sales by (0.2)%. Net

sales in constant currency increased 5.9% from increased unit

volume. The unit volume increase was due to higher shipments

primarily within the Ortho Tech and Trauma and Extremities

businesses.

Orthopaedics net sales increased 4.9% in the nine months 2026

as reported and 4.1% in constant currency, as foreign currency

exchange rates positively impacted net sales by 0.8%. Excluding

the (2.1)% impact of acquisitions and divestitures, net sales in

constant currency increased 6.2% from increased unit volume.

The unit volume increase was due to higher shipments across

most Orthopaedics businesses.

Gross Profit

Gross profit was $4,248 and $3,852 in the three months 2026

and 2025. The key components of the change were:

Gross Profit Percent Net Sales
Three Months 2025 63.6%
Volume and mix 60 bps
Manufacturing and supply chain costs (20) bps
Structural optimization and other special charges 20 bps
Inventory stepped up to fair value 100 bps
Three Months 2026 65.2%

Gross profit as a percentage of net sales in the three months

2026 increased to 65.2% from 63.6% in 2025 primarily driven by

lower amortization of inventory stepped up to fair value.

Gross profit was $12,556 and $11,437 in the nine months 2026

and 2025. The key components of the change were:

Gross Profit Percent Net Sales
Nine Months 2025 63.7%
Sales pricing 10 bps
Volume and mix 50 bps
Manufacturing and supply chain costs (80) bps
Structural optimization and other special charges 30 bps
Inventory stepped up to fair value 90 bps
Reversal of 2025 tariffs 90 bps
Nine Months 2026 65.6%

Gross profit as a percentage of net sales in the nine months 2026

increased to 65.6% from 63.7% in 2025 driven by a reduction of

certain import tariffs and lower amortization of inventory stepped

up to fair value partially offset by higher manufacturing and

supply chain costs primarily due to idle production time related to

the cybersecurity incident in the first quarter 2026.

While segment mix was not a significant driver of the change in

gross profit as a percent of net sales between the nine months

2026 and 2025, we generally expect segment mix to have an

unfavorable impact for the foreseeable future as we anticipate

more rapid sales growth in our lower gross margin MedSurg and

Neurotechnology segment than our Orthopaedics segment.

Research, Development and Engineering Expenses

Research, development and engineering expenses increased

$23 or 5.6% in the three months 2026 and $58 or 4.7% in the

nine months 2026. Expenses as a percentage of net sales of

6.6% in the three months and 6.7% in the nine months 2026

remained relatively flat with 6.8% in the three and nine months

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased $268 or

13.1% in the three months 2026. As a percentage of net sales,

expenses increased to 35.5% from 33.8% in 2025, primarily due

to higher structural optimization and other special charges.

Selling, general and administrative expenses increased $399 or

6.2% in the nine months 2026. Expenses as a percentage of net

sales of 35.7% remained relatively flat with 35.8% in 2025.

Higher structural optimization and other special charges in the

nine months 2026 were offset by lower acquisition and

integration-related costs.

Amortization of Intangible Assets

Amortization of intangible assets was $175 and $189 in the three

months and $530 and $543 in the nine months 2026 and 2025.

Refer to Note 7 to our Consolidated Financial Statements for

further information.

Goodwill and Other Impairments

We recorded a goodwill impairment charge of $293 in the three

months 2026 related to our Peripheral Vascular business. Refer

to Note 11 to our Consolidated Financial Statements for further

information.

We recorded other impairments of $73 in the three months 2025

and $1 and $163 in the nine months 2026 and 2025.

Operating Income

Operating income was $1,034 and $1,135 in the three months

2026 and 2025. Operating income as a percentage of net sales in

the three months 2026 decreased to 15.9% from 18.7% in 2025.

Refer to the discussion above for the primary drivers of the

change.

Dollar amounts are in millions except per share amounts or as otherwise specified. 14

STRYKER CORPORATION 2026 Third Quarter Form 10-Q

Operating income was $3,629 and $3,085 in the nine months

2026 and 2025. Operating income as a percentage of net sales in

the nine months 2026 increased to 19.0% from 17.2% in 2025.

Refer to the discussion above for the primary drivers of the

change.

MedSurg and Neurotechnology operating income as a

percentage of net sales increased to 28.7% in the three months

2026 from 26.1% in 2025. Orthopaedics operating income as a

percentage of net sales decreased to 31.2% in the three months

2026 from 32.4% in 2025. The key components of the change

were:

Operating Income Percent Net Sales MedSurg and Neurotechnology Orthopaedics
Three Months 2025 26.1% 32.4%
Sales pricing 10 bps 0 bps
Volume 70 bps 40 bps
Manufacturing and supply chain costs 50 bps (70) bps
Research, development and engineering expenses 20 bps 20 bps
Selling, general and administrative expenses 110 bps (110) bps
Three Months 2026 28.7% 31.2%

The increase in MedSurg and Neurotechnology operating income

as a percentage of net sales for the three months was primarily

driven by lower selling, general and administrative expenses,

lower manufacturing and supply chain costs and higher unit

volumes.

The decrease in Orthopaedics operating income as a percentage

of net sales for the three months was primarily driven by higher

selling, general and administrative expenses and higher

manufacturing and supply chain costs, partially offset by higher

unit volumes.

MedSurg and Neurotechnology operating income as a

percentage of net sales increased to 26.4% in the nine months

2026 from 25.5% in 2025. Orthopaedics operating income as a

percentage of net sales decreased to 31.8% in the nine months

2026 from 32.0% in 2025. The key components of the change

were:

Operating Income Percent Net Sales MedSurg and Neurotechnology Orthopaedics
Nine Months 2025 25.5% 32.0%
Sales pricing 10 bps 0 bps
Volume 50 bps 30 bps
Manufacturing and supply chain costs (20) bps (90) bps
Research, development and engineering expenses (10) bps 30 bps
Selling, general and administrative expenses 60 bps 10 bps
Nine Months 2026 26.4% 31.8%

The increase in MedSurg and Neurotechnology operating income

as a percentage of net sales for the nine months was primarily

driven by lower selling, general and administrative expenses and

higher unit volumes, partially offset by higher manufacturing and

supply chain costs and higher research, development and

engineering expenses.

The decrease in Orthopaedics operating income as a percentage

of net sales for the nine months was primarily driven by higher

manufacturing and supply chain costs, partially offset by lower

research, development and engineering expenses, lower selling,

general and administrative expenses and higher unit volumes.

Interest Expense

Interest expense was $143 and $157 in the three months and

$432 and $453 in the nine months 2026 and 2025. The decrease

in interest expense in the three and nine months 2026 from 2025

was due to lower outstanding debt and credit facilities partially

offset by higher average interest rates.

Other Income

Other income was $106 and $51 in the three months and $214

and $177 in the nine months 2026 and 2025. The increase in

other income in the three and nine months 2026 from 2025 was

primarily due to income from intellectual property licensing in

Income Taxes

Our effective tax rates were 24.5% and 18.7% in the three and

nine months 2026 and 16.5% and 14.7% in the three and nine

months 2025. The effective tax rate for the three months 2026

increased from the three months 2025 due to the 2026 non-

deductible goodwill impairment. The effective tax rate for the nine

months 2026 increased from the nine months 2025 due to the

2026 non-deductible goodwill impairment and the 2025 tax

benefit related to the sale of the Spinal Implants business. The

effective tax rates for the three and nine months 2026 and 2025

reflect the continued lower effective income tax rates as a result

of our European operations and certain discrete tax items.

Our future results of operations could be affected by changes in

the effective tax rate as a result of changes in tax laws,

regulations and judicial rulings. We are continuing to evaluate the

impact of tax reform in the countries in which we operate as new

guidance is published and new regulations are adopted.

Net Earnings

Net earnings decreased to $753 or $1.96 per diluted share in the

three months 2026 from $859 or $2.22 per diluted share in 2025.

Net earnings increased to $2,774 or $7.19 per diluted share in

the nine months 2026 from $2,397 or $6.20 per diluted share in

2025. Refer to the discussion above for the primary drivers of the

change.

Non-GAAP Financial Measures

We supplement the reporting of our financial information

determined under accounting principles generally accepted in the

United States (GAAP) with certain non-GAAP financial measures,

including percentage sales growth in constant currency;

percentage organic sales growth; adjusted gross profit; adjusted

selling, general and administrative expenses; adjusted research,

development and engineering expenses; adjusted operating

income; adjusted other income (expense), net; adjusted income

taxes; adjusted effective income tax rate; adjusted net earnings;

and adjusted net earnings per diluted share (Diluted EPS). We

believe these non-GAAP financial measures provide meaningful

information to assist investors and shareholders in understanding

our financial results and assessing our prospects for future

performance. Management believes percentage sales growth in

constant currency and the other adjusted measures described

above are important indicators of our operations because they

exclude items that may not be indicative of or are unrelated to our

core operating results and provide a baseline for analyzing trends

in our underlying businesses. Management uses these non-

GAAP financial measures for reviewing the operating results of

reportable business segments and analyzing potential future

business trends in connection with our budget process and bases

certain management incentive compensation on these non-GAAP

financial measures. To measure percentage sales growth in

Dollar amounts are in millions except per share amounts or as otherwise specified. 15

STRYKER CORPORATION 2026 Third Quarter Form 10-Q

constant currency, we remove the impact of changes in foreign

currency exchange rates that affect the comparability and trend

of sales. Percentage sales growth in constant currency is

calculated by translating current and prior year results at the

same foreign currency exchange rate. To measure percentage

organic sales growth, we remove the impact of changes in

foreign currency exchange rates, acquisitions and divestitures,

which affect the comparability and trend of sales. Percentage

organic sales growth is calculated by translating current year and

prior year results at the same foreign currency exchange rates

excluding the impact of acquisitions and divestitures. To measure

earnings performance on a consistent and comparable basis, we

exclude certain items that affect the comparability of operating

results and the trend of earnings. The income tax effect of each

adjustment was determined based on the tax effect of the

jurisdiction in which the related pre-tax adjustment was recorded.

These adjustments are irregular in timing and may not be

indicative of our past and future performance. The following are

examples of the types of adjustments that may be included in a

period:

1. Acquisition and integration-related costs. Costs related to

integrating recently acquired businesses (e.g., costs

associated with the termination of sales relationships,

employee retention and workforce reductions, manufacturing

integration costs and other integration-related activities),

changes in the fair value of contingent consideration,

amortization of inventory stepped-up to fair value, specific

costs (e.g., deal costs and costs associated with legal entity

rationalization) related to the consummation of the

acquisition process and legal entity rationalization and

acquisition-related tax items.

2. Amortization of purchased intangible assets. Periodic

amortization expense related to purchased intangible assets.

3. Structural optimization and other special charges. Costs

associated with employee retention and workforce

reductions, the closure or transfer of manufacturing and

other facilities (e.g., site closure costs, contract termination

costs and redundant employee costs during the work

transfers), product line exits (primarily inventory, long-lived

asset and specifically-identified intangible asset write-offs),

certain long-lived and intangible asset write-offs and

impairments and other charges.

4. Medical device regulations. Costs specific to updating our

quality system, product labeling, asset write-offs and product

remanufacturing to comply with the new medical device

reporting regulations and other requirements of the

European Union.

5. Recall-related matters. Changes in our best estimate of the

probable loss, or the minimum of the range of probable

losses when a best estimate within a range is not known, to

resolve the Rejuvenate, LFIT V40, Wright legacy hip

products and other product recalls.

6. Regulatory and legal matters. Changes in our best estimate

of the probable loss, or the minimum of the range of

probable losses when a best estimate within a range is not

known, to resolve certain regulatory or other legal matters

and the amount of favorable awards from settlements.

7. Tax matters. Impact of accounting for certain significant and

discrete tax items.

Because non-GAAP financial measures are not standardized, it

may not be possible to compare these financial measures with

other companies' non-GAAP financial measures having the same

or similar names. These adjusted financial measures should not

be considered in isolation or as a substitute for reported sales

growth, gross profit, selling, general and administrative expenses,

research, development and engineering expenses, operating

income, other income (expense), net, income taxes, effective

income tax rate, net earnings and net earnings per diluted share,

the most directly comparable GAAP financial measures. These

non-GAAP financial measures are an additional way of viewing

aspects of our operations when viewed with our GAAP results

and the reconciliations to corresponding GAAP financial

measures at the end of the discussion of Consolidated Results of

Operations below. We strongly encourage investors and

shareholders to review our financial statements and publicly-filed

reports in their entirety and not to rely on any single financial

measure.

The weighted-average diluted shares outstanding used in the

calculation of adjusted net earnings per diluted share are the

same as those used in the calculation of reported net earnings

per diluted share for the respective period.

Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

Three Months 2026 Gross Profit Selling, General & Administrative Expenses Research, Development & Engineering Expenses Operating Income Other Income (Expense), Net Income Taxes Net Earnings Effective Tax Rate Diluted EPS
Reported $4,248 $2,313 $433 $1,034 $(37) $244 $753 24.5% $1.96
Reported percent net sales 65.2% 35.5% 6.6% 15.9% (0.6)% nm 11.5%
Acquisition and integration-related costs:
Inventory stepped-up to fair value — — — — — — — — —
Other acquisition and integration-related (a) 6 (5) (6) 17 — 3 14 — 0.04
Amortization of purchased intangible assets — — — 175 — 33 142 0.5 0.37
Structural optimization and other special charges (b) 12 (137) (4) 153 (54) 23 76 0.8 0.20
Goodwill and other impairments (c) — — — 293 — — 293 (4.8) 0.76
Medical device regulations (d) — — (6) 6 — 1 5 — 0.01
Recall-related matters (e) — 4 — (4) — (2) (2) (0.1) —
Regulatory and legal matters (f) — (32) — 32 — 6 26 0.1 0.07
Tax matters (g) — — — — — (50) 50 (5.0) 0.11
Reversal of 2025 tariffs — — — — — — — — —
Adjusted $4,266 $2,143 $417 $1,706 $(91) $258 $1,357 16.0% $3.52
Adjusted percent net sales 65.4% 32.8% 6.4% 26.2% (1.4)% nm 20.8%

Dollar amounts are in millions except per share amounts or as otherwise specified. 16

STRYKER CORPORATION 2026 Third Quarter Form 10-Q

Three Months 2025 Gross Profit Selling, General & Administrative Expenses Research, Development & Engineering Expenses Operating Income Other Income (Expense), Net Income Taxes Net Earnings Effective Tax Rate Diluted EPS
Reported $3,852 $2,045 $410 $1,135 $(106) $170 $859 16.5% $2.22
Reported percent net sales 63.6% 33.8% 6.8% 18.7% (1.8)% nm 14.2%
Acquisition and integration-related costs:
Inventory stepped-up to fair value 61 — — 61 — 15 46 0.6 0.12
Other acquisition and integration-related (a) 5 (33) (1) 39 — 6 33 0.1 0.08
Amortization of purchased intangible assets — — — 189 — 39 150 1.2 0.39
Structural optimization and other special charges (b) 15 (26) — 41 (10) 3 28 (0.1) 0.07
Goodwill and other impairments (c) — — — 73 — 15 58 0.4 0.16
Medical device regulations (d) — — (11) 11 — 3 8 0.1 0.02
Recall-related matters (e) — (1) — 1 — — 1 — —
Regulatory and legal matters (f) — — — — — — — — —
Tax matters (g) — — — — — (50) 50 (4.8) 0.13
Adjusted $3,933 $1,985 $398 $1,550 $(116) $201 $1,233 14.0% $3.19
Adjusted percent net sales 65.0% 32.8% 6.6% 25.6% (1.9)% nm 20.4%

nm - not meaningful

(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:

Three Months 2026 2025
Termination of sales relationships $1 $—
Employee retention and workforce reductions 1 11
Changes in the fair value of contingent consideration 1 12
Manufacturing integration costs 17 7
Other integration-related activities (3) 9
Adjustments to Operating Income $17 $39
Adjustments to Income Taxes $3 $6
Adjustments to Net Earnings $14 $33

(b) Structural optimization and other special charges represent the costs associated with:

Three Months 2026 2025
Employee retention and workforce reductions $7 $6
Closure/transfer of manufacturing and other facilities 8 8
Product line exits (5) 9
Termination of sales relationships in certain countries 37 2
Spinal Implants sale related 77 9
Other charges 29 7
Adjustments to Operating Income $153 $41
Adjustments to Other Income (Expense), Net $(54) $(10)
Adjustments to Income Taxes $23 $3
Adjustments to Net Earnings $76 $28

(c) Goodwill and other impairments represent the costs associated with:

Three Months 2026 2025
Goodwill impairment $293 $—
Certain long-lived and intangible asset write-offs and impairments — 22
Product line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs) — 51
Adjustments to Operating Income $293 $73
Adjustments to Income Taxes $— $15
Adjustments to Net Earnings $293 $58

(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device

reporting regulations and other requirements of the new medical device regulations in the European Union.

(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to

resolve certain recall-related matters.

(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to

resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.

Dollar amounts are in millions except per share amounts or as otherwise specified. 17

STRYKER CORPORATION 2026 Third Quarter Form 10-Q

(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:

Three Months 2026 2025
Adjustments related to the transfer of certain intellectual properties between tax jurisdictions $(56) $(61)
Other tax matters 6 11
Adjustments to Income Taxes $(50) $(50)
Adjustments to Other Income (Expense), Net $— $—
Adjustments to Net Earnings $50 $50

Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

Nine Months 2026 Gross Profit Selling, General & Administrative Expenses Research, Development & Engineering Expenses Operating Income Other Income (Expense), Net Income Taxes Net Earnings Effective Tax Rate Diluted EPS
Reported $12,556 $6,823 $1,280 $3,629 $(218) $637 $2,774 18.7% $7.19
Reported percent net sales 65.6% 35.7% 6.7% 19.0% (1.1)% nm 14.5%
Acquisition and integration-related costs:
Inventory stepped-up to fair value — — — — — — — — —
Other acquisition and integration-related (a) 15 (32) (14) 61 — 10 51 — 0.14
Amortization of purchased intangible assets — — — 530 — 96 434 0.4 1.12
Structural optimization and other special charges (b) 31 (330) (5) 366 (71) 68 227 0.6 0.59
Goodwill and other impairments (c) — — — 294 — — 294 (1.3) 0.76
Medical device regulations (d) — — (16) 16 — 3 13 — 0.03
Recall-related matters (e) — (8) — 8 — 1 7 — 0.02
Regulatory and legal matters (f) — (38) — 38 — 7 31 — 0.08
Tax matters (g) — — — — — (87) 87 (2.6) 0.22
Reversal of 2025 tariffs (158) — — (158) — (25) (133) — (0.34)
Adjusted $12,444 $6,415 $1,245 $4,784 $(289) $710 $3,785 15.8% $9.81
Adjusted percent net sales 65.1% 33.5% 6.5% 25.0% (1.5)% nm 19.8%
Nine Months 2025 Gross Profit Selling, General & Administrative Expenses Research, Development & Engineering Expenses Operating Income Other Income (Expense), Net Income Taxes Net Earnings Effective Tax Rate Diluted EPS
Reported $11,437 $6,424 $1,222 $3,085 $(276) $412 $2,397 14.7% $6.20
Reported percent net sales 63.7% 35.8% 6.8% 17.2% (1.5)% nm 13.4%
Acquisition and integration-related costs:
Inventory stepped-up to fair value 160 — — 160 — 39 121 0.5 0.31
Other acquisition and integration-related (a) 19 (280) (3) 302 — 32 270 (0.4) 0.70
Amortization of purchased intangible assets — — — 543 — 112 431 1.2 1.11
Structural optimization and other special charges (b) 43 (47) (3) 93 (19) 15 59 0.2 0.15
Goodwill and other impairments (c) — — — 163 — 46 117 0.8 0.32
Medical device regulations (d) 1 — (29) 30 — 7 23 0.1 0.06
Recall-related matters (e) 52 (4) — 56 — 9 47 — 0.12
Regulatory and legal matters (f) — (7) — 7 — 2 5 — 0.01
Tax matters (g) — — — — — (71) 71 (2.5) 0.18
Adjusted $11,712 $6,086 $1,187 $4,439 $(295) $603 $3,541 14.6% $9.16
Adjusted percent net sales 65.3% 33.9% 6.6% 24.7% (1.6)% nm 19.7%

nm - not meaningful

(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:

Nine Months 2026 2025
Termination of sales relationships $7 $—
Employee retention and workforce reductions 1 56
Changes in the fair value of contingent consideration 10 13
Manufacturing integration costs 27 14
Stock compensation payments upon a change in control — 139
Other integration-related activities 16 80
Adjustments to Operating Income $61 $302
Adjustments to Income Taxes $10 $32
Adjustments to Net Earnings $51 $270

Dollar amounts are in millions except per share amounts or as otherwise specified. 18

STRYKER CORPORATION 2026 Third Quarter Form 10-Q

(b) Structural optimization and other special charges represent the costs associated with:

Nine Months 2026 2025
Employee retention and workforce reductions $20 $36
Closure/transfer of manufacturing and other facilities 17 20
Product line exits 6 2
Termination of sales relationships in certain countries 124 (2)
Spinal Implants sale related 128 17
Other charges 71 20
Adjustments to Operating Income $366 $93
Adjustments to Other Income (Expense), Net $(71) $(19)
Adjustments to Income Taxes $68 $15
Adjustments to Net Earnings $227 $59

(c) Goodwill and other impairments represent the costs associated with:

Nine Months 2026 2025
Goodwill impairment $293 $—
Certain long-lived and intangible asset write-offs and impairments — 108
Product line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs) 1 55
Adjustments to Operating Income $294 $163
Adjustments to Income Taxes $— $46
Adjustments to Net Earnings $294 $117

(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device

reporting regulations and other requirements of the new medical device regulations in the European Union.

(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to

resolve certain recall-related matters.

(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to

resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.

(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:

Nine Months 2026 2025
Adjustments related to the transfer of certain intellectual properties between tax jurisdictions $(131) $(153)
Other tax matters 44 82
Adjustments to Income Taxes $(87) $(71)
Adjustments to Other Income (Expense), Net $— $—
Adjustments to Net Earnings $87 $71

FINANCIAL CONDITION AND LIQUIDITY

Net cash provided by (used in): Nine Months 2026 2025
Operating activities $3,303 $2,901
Investing activities (1,011) (4,561)
Financing activities (2,998) 1,206
Effect of exchange rate changes (34) 58
Change in cash and cash equivalents $(740) $(396)

Operating Activities

Cash provided by operating activities was $3,303 and $2,901 in

the nine months 2026 and 2025. The increase was primarily due

to higher net earnings partially offset by changes in working

capital.

Investing Activities

Cash used in investing activities was $1,011 and $4,561 in the

nine months 2026 and 2025. The nine months 2026 included

cash paid for purchases of property, plant and equipment as well

as for the net cash consideration paid to complete the acquisition

of AVS. The nine months 2025 included cash paid to acquire Inari

and purchases of property, plant and equipment partially offset by

proceeds from the sale of short-term investments. Refer to Note

7 to our Consolidated Financial Statements for further information

on acquisitions.

Financing Activities

Cash used in financing activities was $2,998 in the nine months

2026 and cash provided by financing activities was $1,206 in the

nine months 2025. In 2026 cash used was primarily driven by

repayments of $1,000 to pay off maturing unsecured notes as

described in Note 8 to our Consolidated Financial Statements,

$1,000 repurchases of common stock and dividend payments.

Cash provided by financing activities in 2025 was primarily driven

by proceeds from the issuance of various senior unsecured notes

partially offset by dividend payments.

Liquidity

Cash, cash equivalents, short-term investments and marketable

securities were $3,271 and $4,100 on September 30, 2026 and

December 31, 2025. Current assets exceeded current liabilities

by $7,683 and $6,961 on September 30, 2026 and December 31,

2025. We anticipate being able to support our short-term liquidity

and operating needs from a variety of sources including cash

from operations, commercial paper and existing credit lines.

We have raised funds in the capital markets and have accessed

the credit markets in the past and may continue to do so from

time-to-time. We continue to have strong investment-grade short-

term and long-term debt ratings that we believe should enable us

to refinance our debt as needed.

Our cash, cash equivalents, short-term investments and

marketable securities held in locations outside the United States

Dollar amounts are in millions except per share amounts or as otherwise specified. 19

STRYKER CORPORATION 2026 Third Quarter Form 10-Q

was approximately 44% on September 30, 2026 compared to

20% on December 31, 2025.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There were no changes to our critical accounting policies and

estimates from those disclosed in our Annual Report on Form 10-

K for 2025, except as follows:

We test goodwill annually for impairment at October 31 or

whenever events or circumstances indicate that goodwill may be

impaired. When it is unlikely that goodwill of a reporting unit is

impaired, we perform a qualitative assessment that may be

periodically supplemented with a corroborative quantitative

analysis.

The Peripheral Vascular business’s operating results have been

affected by a reduction in forecasted cash flows reflecting near-

term operational and supply constraints and a longer expected

period to achieve anticipated growth and market recovery. These

inputs were included in the updated projections used in our

annual long-range financial plan, which was approved during the

third quarter 2026. As a result of these factors, we performed an

interim impairment assessment of goodwill, indefinite-lived and

other long-lived assets of the Peripheral Vascular reporting unit

and a charge of $293 was recognized in goodwill and other

impairments in the Consolidated Statements of Earnings.

Goodwill attributable to the Peripheral Vascular reporting unit was

approximately $3,259 at September 30, 2026.

In our interim quantitative goodwill impairment test, the fair value

of our Peripheral Vascular reporting unit was determined using a

discounted cash flow analysis, which is a form of the income

approach. Significant inputs to the analysis included assumptions

for future revenue growth, operating margin, the effective tax rate

applied to future earnings and the rate used to discount the

estimated future cash flows to their present value based on the

reporting unit’s estimated weighted average cost of capital. Our

assumptions for revenue growth and operating margin

considered several operating factors, including supply constraints

and our competitive environment. We believe our estimates are

appropriate based upon current and future market conditions and

the best information available at the impairment assessment

date; however, future impairment charges could be required if our

Peripheral Vascular reporting unit does not achieve its cash flow,

revenue and profitability projections or if there is an increase in

the weighted average cost of capital.

The assumptions used in the discounted cash flow analysis are

subject to inherent uncertainties and subjectivity. The use of

different assumptions, estimates or judgments with respect to the

estimation of future cash flows and the determination of the

discount rate used to reduce such estimated future cash flows to

their net present value could materially affect the determination of

any impairment charges. Hypothetical changes in our estimates

of the discount rate, long-term revenue growth and long-term

operating margin would result in incremental impairment charges

as follows:

Change in selected assumption Percentage decline in fair value Incremental impairment charge
100 bps increase in discount rate 15% $823
100 bps decrease in long-term revenue growth 3 145
100 bps decrease in long-term operating margin 9 497

Refer to Note 11 to our Consolidated Financial Statements for

discussion on the impact of changes to our organizational

structure in the first quarter 2026 on our reportable segments and

the related goodwill.

Guarantees and Other Off-Balance Sheet Arrangements

We do not have guarantees or other off-balance sheet financing

arrangements, including variable interest entities, of a magnitude

that we believe could have a material impact on our financial

condition or liquidity.

OTHER MATTERS

Legal and Regulatory Matters

We are involved in various ongoing proceedings, legal actions

and claims arising in the normal course of our business, including

proceedings related to product, labor, tax, intellectual property

and other matters. Refer to Note 6 to our Consolidated Financial

Statements for further information.

FORWARD-LOOKING STATEMENTS

This report contains statements that are not historical facts and

are considered "forward-looking statements" within the meaning

of the Private Securities Litigation Reform Act of 1995. These

statements are based on current projections about operations,

industry conditions, financial condition and liquidity. Words that

identify forward-looking statements include, without limitation,

words such as "may," "could," "will," "should," "possible," "plan,"

"predict," "forecast," "potential," "anticipate," "estimate," "expect,"

"project," "intend," "believe," "may impact," "on track," "goal,"

"strategy" and words and terms of similar substance used in

connection with any discussion of future operating or financial

performance, an acquisition or our businesses. In addition, any

statements that refer to expectations, projections or other

characterizations of future events or circumstances, including any

underlying assumptions, are forward-looking statements. Those

statements are not guarantees and are subject to risks,

uncertainties and assumptions that are difficult to predict,

including uncertainties related to the impact of the cybersecurity

incident first reported on March 11, 2026 on our operations and

financial results. Therefore, actual results could differ materially

and adversely from these forward-looking statements, historical

experience or our present expectations. Some important factors

that could cause our actual results to differ from our expectations

in any forward-looking statements include the risks discussed in

Market risk

As filed, 525 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We consider our greatest potential area of market risk exposure

to be exchange rate risk on our operating results. Quantitative

and qualitative disclosures about exchange rate risk are included

in Item 7A "Quantitative and Qualitative Disclosures About Market

Risk" of our Annual Report on Form 10-K for 2025. There were

no material changes from the information provided therein.

Dollar amounts are in millions except per share amounts or as otherwise specified. 20

STRYKER CORPORATION 2026 Third Quarter Form 10-Q

Controls and procedures

As filed, 823 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of the Chief Executive

Officer and Chief Financial Officer (the Certifying Officers),

evaluated the effectiveness of the Company's disclosure controls

and procedures (as defined in Rules 13a-15(e) or 15d-15(e)

promulgated under the Securities Exchange Act of 1934, as

amended) on September 30, 2026. Based on that evaluation, the

Certifying Officers concluded the Company's disclosure controls

and procedures were effective as of September 30, 2026.

Changes in Internal Control Over Financial Reporting

There was no change to our internal control over financial

reporting during the nine months 2026 that materially affected, or

is reasonably likely to materially affect, our internal control over

financial reporting.

Risk factors

As filed, 895 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

2025. This Form 10-Q should be read in conjunction with our

Consolidated Financial Statements and accompanying notes to

our Consolidated Financial Statements in our Annual Report on

Form 10-K for 2025. While we believe that the assumptions

underlying such forward-looking statements are reasonable,

there can be no assurance that future events or developments

will not cause such statements to be inaccurate. All forward-

looking statements contained in this report are qualified in their

entirety by this cautionary statement. We expressly disclaim any

intention or obligation to publicly update or revise any forward-

looking statement to reflect any change in our expectations or in

events, conditions or circumstances on which those expectations

may be based, or that affect the likelihood that actual results will

differ from those contained in the forward-looking statements.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2026-07-01 to 2026-09-30$6.52bnus-gaap:Revenues
Revenue9 months2026-01-01 to 2026-09-30$19.13bnus-gaap:Revenues
Cost of revenue3 months2026-07-01 to 2026-09-30$2.27bnus-gaap:CostOfRevenue
Cost of revenue9 months2026-01-01 to 2026-09-30$6.57bnus-gaap:CostOfRevenue
Gross profit3 months2026-07-01 to 2026-09-30$4.25bnus-gaap:GrossProfit
Gross profit9 months2026-01-01 to 2026-09-30$12.56bnus-gaap:GrossProfit
Research and development3 months2026-07-01 to 2026-09-30$433.0mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2026-01-01 to 2026-09-30$1.28bnus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2026-07-01 to 2026-09-30$2.31bnus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2026-01-01 to 2026-09-30$6.82bnus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2026-07-01 to 2026-09-30$1.03bnus-gaap:OperatingIncomeLoss
Operating income9 months2026-01-01 to 2026-09-30$3.63bnus-gaap:OperatingIncomeLoss
Interest expense3 months2026-07-01 to 2026-09-30$143.0mus-gaap:InterestExpenseNonoperating
Interest expense9 months2026-01-01 to 2026-09-30$432.0mus-gaap:InterestExpenseNonoperating
Income tax3 months2026-07-01 to 2026-09-30$244.0mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2026-01-01 to 2026-09-30$637.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2026-07-01 to 2026-09-30$753.0mus-gaap:NetIncomeLoss
Net income9 months2026-01-01 to 2026-09-30$2.77bnus-gaap:NetIncomeLoss
Diluted EPS3 months2026-07-01 to 2026-09-30$1.96us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2026-01-01 to 2026-09-30$7.19us-gaap:EarningsPerShareDiluted
Basic EPS3 months2026-07-01 to 2026-09-30$1.97us-gaap:EarningsPerShareBasic
Basic EPS9 months2026-01-01 to 2026-09-30$7.24us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2026-07-01 to 2026-09-30384,700,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2026-01-01 to 2026-09-30385,800,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2026-01-01 to 2026-09-30$3.30bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2026-01-01 to 2026-09-30$605.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2026-01-01 to 2026-09-30$1.01bnus-gaap:PaymentsOfDividends
Share repurchases9 months2026-01-01 to 2026-09-30$1.00bnus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2026-09-30$3.27bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2026-09-30$14.18bnus-gaap:AssetsCurrent
Total assetsAt period end2026-09-30$47.25bnus-gaap:Assets
Current liabilitiesAt period end2026-09-30$6.50bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2026-09-30$23.79bnus-gaap:Liabilities
Long-term debtAt period end2026-09-30$14.18bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2026-09-30$754.0mus-gaap:DebtCurrent
Short-term borrowingsAt period end2026-09-30$250.0mus-gaap:CommercialPaper
Shareholders' equityAt period end2026-09-30$23.46bnus-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
Shares outstandingAt period end2026-09-30380,691,004 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0000310764-26-000061. Last ingested by Listed: Nov 10, 2026, 03:05 ET. Listed shows no prices and gives no investment advice.